This inventor holds 1 USPTO granted patent. Top assignee: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2010.
Company Filing History:
Years Active: 2010
Title: Stephanie Lamer: Innovator in Immunization and Diagnostics
Introduction
Stephanie Lamer is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of immunization and diagnostics through her innovative research. Her work focuses on identifying specific differentially expressed antigens that can be utilized for immunization against pathogenic organisms.
Latest Patents
Stephanie Lamer holds 1 patent titled "Identification of specific differentially expressed antigens." This invention relates to compositions that are useful in immunization against pathogenic organisms and for diagnostic purposes. The patent details a composition comprising at least one protein that is differentially expressed in a virulent strain compared to an avirulent strain. Additionally, it encompasses fusion proteins, antigenic fragments, nucleic acid molecules encoding the aforementioned proteinaceous compounds, and antibodies. The invention also includes pharmaceutical and diagnostic compositions that utilize these compounds for treating induced diseases and preparing vaccines.
Career Highlights
Stephanie Lamer is affiliated with the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V., a leading research institution in Germany. Her work has been instrumental in advancing the understanding of immunological responses and developing new therapeutic strategies.
Collaborations
Throughout her career, Stephanie has collaborated with notable colleagues, including Ulrich E. Schaible and Ursula Zimny-Arndt. These collaborations have further enriched her research and contributed to the success of her innovative projects.
Conclusion
Stephanie Lamer is a dedicated inventor whose work in immunization and diagnostics has the potential to impact public health significantly. Her innovative approaches and collaborations continue to drive advancements in the field.
